注意欠陥・多動性障害（ADHD）治療薬の世界市場（～2026年）

• 英文タイトル：Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size, Status and Forecast 2020-2026

• レポートコード：MRC2-11QY10921 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、91ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：ヘルスケア

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ
Enterprise License	￥1,154,400 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

当調査資料は注意欠陥・多動性障害（ADHD）治療薬のグローバル市場について調査・分析したレポートです。種類別（覚醒剤、非覚醒剤）市場規模、用途別（専門クリニック、病院薬局、小売薬局、Eコマース）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別注意欠陥・多動性障害（ADHD）治療薬の競争状況、市場シェア ・世界の注意欠陥・多動性障害（ADHD）治療薬市場：種類別市場規模 2015年-2020年（覚醒剤、非覚醒剤） ・世界の注意欠陥・多動性障害（ADHD）治療薬市場：種類別市場規模予測 2021年-2026年（覚醒剤、非覚醒剤） ・世界の注意欠陥・多動性障害（ADHD）治療薬市場：用途別市場規模 2015年-2020年（専門クリニック、病院薬局、小売薬局、Eコマース） ・世界の注意欠陥・多動性障害（ADHD）治療薬市場：用途別市場規模予測 2021年-2026年（専門クリニック、病院薬局、小売薬局、Eコマース） ・北米の注意欠陥・多動性障害（ADHD）治療薬市場分析：米国、カナダ ・ヨーロッパの注意欠陥・多動性障害（ADHD）治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの注意欠陥・多動性障害（ADHD）治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の注意欠陥・多動性障害（ADHD）治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの注意欠陥・多動性障害（ADHD）治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Eli Lilly and Company、Novartis、Takeda、Pfizer、GlaxoSmithKline、Mallinckrodt Pharmaceuticals、Hisamitsu Pharmaceutical、Impax Laboratories、Johnson ＆Johnson、UCB、Purdue Parma ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論

ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.
Growth in the ADHD therapeutics market is mainly driven by granular impact of changing lifestyles and value systems impacting quality of births, increasing use of additives and preservations in children’s diet, rising prevalence of ADHD among children in the 4–17 year age group, increasing adoption of diagnostic guidelines (statistical manual of mental disorders) with low threshold for diagnosis of ADHD in other regions such as Europe and Latin America. Moreover, increasing awareness regarding ADHD among physicians and patients, and opinion-based diagnosis of ADHD owing to lack of standard diagnostic tests is expected to boost revenue growth of the global ADHD therapeutics market in the near future. However, existence of comorbid conditions in children leads to underdiagnoses of ADHD and less availability of non-stimulants ADHD drugs in various geographies. These are factors expected to restrain growth of the market over the forecast period.

Market Analysis and Insights: Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
The global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.

Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Scope and Market Size
Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

The key players covered in this study
Eli Lilly and Company
Novartis
Takeda
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson ＆Johnson
UCB
Purdue Parma

Market segment by Type, the product can be split into
Stimulants
Non-Stimulants
Market segment by Application, split into
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue
1.4 Market by Type
1.4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Stimulants
1.4.3 Non-Stimulants
1.5 Market by Application
1.5.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2020 VS 2026
1.5.2 Specialty Clinics
1.5.3 Hospital Pharmacies
1.5.4 Retail Pharmacies
1.5.5 E-Commerce
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Perspective (2015-2026)
2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Growth Trends by Regions
2.2.1 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Share by Regions (2015-2020)
2.2.3 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Strategy
2.3.6 Primary Interviews with Key Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players (Opinion Leaders)

3 Competition Landscape by Key Players
3.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Market Size
3.1.1 Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Revenue (2015-2020)
3.1.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Players (2015-2020)
3.1.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio
3.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2019
3.3 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players Head office and Area Served
3.4 Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
3.5 Date of Enter into Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)
4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Historic Market Size by Type (2015-2020)
4.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)
5.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)
5.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Application (2021-2026)

6 North America
6.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
6.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in North America (2019-2020)
6.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
6.4 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

7 Europe
7.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
7.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in Europe (2019-2020)
7.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
7.4 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

8 China
8.1 China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
8.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in China (2019-2020)
8.3 China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
8.4 China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

9 Japan
9.1 Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
9.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in Japan (2019-2020)
9.3 Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
9.4 Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

10 Southeast Asia
10.1 Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
10.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
10.4 Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

11 India
11.1 India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
11.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in India (2019-2020)
11.3 India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
11.4 India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

12 Central & South America
12.1 Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (2015-2020)
12.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Players in Central & South America (2019-2020)
12.3 Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020)
12.4 Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020)

13 Key Players Profiles
13.1 Eli Lilly and Company
13.1.1 Eli Lilly and Company Company Details
13.1.2 Eli Lilly and Company Business Overview
13.1.3 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.1.4 Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020))
13.1.5 Eli Lilly and Company Recent Development
13.2 Novartis
13.2.1 Novartis Company Details
13.2.2 Novartis Business Overview
13.2.3 Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.2.4 Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.2.5 Novartis Recent Development
13.3 Takeda
13.3.1 Takeda Company Details
13.3.2 Takeda Business Overview
13.3.3 Takeda Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.3.4 Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.3.5 Takeda Recent Development
13.4 Pfizer
13.4.1 Pfizer Company Details
13.4.2 Pfizer Business Overview
13.4.3 Pfizer Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.4.4 Pfizer Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.4.5 Pfizer Recent Development
13.5 GlaxoSmithKline
13.5.1 GlaxoSmithKline Company Details
13.5.2 GlaxoSmithKline Business Overview
13.5.3 GlaxoSmithKline Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.5.4 GlaxoSmithKline Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.5.5 GlaxoSmithKline Recent Development
13.6 Mallinckrodt Pharmaceuticals
13.6.1 Mallinckrodt Pharmaceuticals Company Details
13.6.2 Mallinckrodt Pharmaceuticals Business Overview
13.6.3 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.6.4 Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.6.5 Mallinckrodt Pharmaceuticals Recent Development
13.7 Hisamitsu Pharmaceutical
13.7.1 Hisamitsu Pharmaceutical Company Details
13.7.2 Hisamitsu Pharmaceutical Business Overview
13.7.3 Hisamitsu Pharmaceutical Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.7.4 Hisamitsu Pharmaceutical Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.7.5 Hisamitsu Pharmaceutical Recent Development
13.8 Impax Laboratories
13.8.1 Impax Laboratories Company Details
13.8.2 Impax Laboratories Business Overview
13.8.3 Impax Laboratories Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.8.4 Impax Laboratories Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.8.5 Impax Laboratories Recent Development
13.9 Johnson ＆Johnson
13.9.1 Johnson ＆Johnson Company Details
13.9.2 Johnson ＆Johnson Business Overview
13.9.3 Johnson ＆Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.9.4 Johnson ＆Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.9.5 Johnson ＆Johnson Recent Development
13.10 UCB
13.10.1 UCB Company Details
13.10.2 UCB Business Overview
13.10.3 UCB Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
13.10.4 UCB Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
13.10.5 UCB Recent Development
13.11 Purdue Parma
10.11.1 Purdue Parma Company Details
10.11.2 Purdue Parma Business Overview
10.11.3 Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Introduction
10.11.4 Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020)
10.11.5 Purdue Parma Recent Development

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details

List of Tables
Table 1. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Key Market Segments
Table 2. Key Players Covered: Ranking by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue
Table 3. Ranking of Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Manufacturers by Revenue (US$ Million) in 2019
Table 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth Rate by Type (US$ Million): 2020 VS 2026
Table 5. Key Players of Stimulants
Table 6. Key Players of Non-Stimulants
Table 7. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Growth by Application (US$ Million): 2020 VS 2026
Table 8. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions (US$ Million): 2020 VS 2026
Table 9. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions (2015-2020) (US$ Million)
Table 10. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2015-2020)
Table 11. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Forecasted Market Size by Regions (2021-2026) (US$ Million)
Table 12. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2021-2026)
Table 13. Market Top Trends
Table 14. Key Drivers: Impact Analysis
Table 15. Key Challenges
Table 16. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Growth Strategy
Table 17. Main Points Interviewed from Key Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players
Table 18. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Players (2015-2020) (Million US$)
Table 19. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players (2015-2020)
Table 20. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2019)
Table 21. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics by Players Market Concentration Ratio (CR5 and HHI)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Product Solution and Service
Table 24. Date of Enter into Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 27. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Share by Type (2015-2020)
Table 28. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Type (2021-2026)
Table 29. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Share by Application (2015-2020)
Table 30. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 31. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Share by Application (2021-2026)
Table 32. North America Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 33. North America Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 34. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 35. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 36. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 37. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 38. Europe Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 39. Europe Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 40. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 41. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 42. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 43. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 44. China Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 45. China Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 46. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 47. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 48. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 49. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 50. Japan Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 51. Japan Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 52. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 53. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 54. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 55. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 56. Southeast Asia Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 57. Southeast Asia Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 58. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 59. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 60. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 61. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 62. India Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 63. India Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 64. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 65. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 66. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 67. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 68. Central & South America Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue (2019-2020) (Million US$)
Table 69. Central & South America Key Players Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share (2019-2020)
Table 70. Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Type (2015-2020) (Million US$)
Table 71. Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type (2015-2020)
Table 72. Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Application (2015-2020) (Million US$)
Table 73. Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application (2015-2020)
Table 74. Eli Lilly and Company Company Details
Table 75. Eli Lilly and Company Business Overview
Table 76. Eli Lilly and Company Product
Table 77. Eli Lilly and Company Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 78. Eli Lilly and Company Recent Development
Table 79. Novartis Company Details
Table 80. Novartis Business Overview
Table 81. Novartis Product
Table 82. Novartis Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 83. Novartis Recent Development
Table 84. Takeda Company Details
Table 85. Takeda Business Overview
Table 86. Takeda Product
Table 87. Takeda Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 88. Takeda Recent Development
Table 89. Pfizer Company Details
Table 90. Pfizer Business Overview
Table 91. Pfizer Product
Table 92. Pfizer Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 93. Pfizer Recent Development
Table 94. GlaxoSmithKline Company Details
Table 95. GlaxoSmithKline Business Overview
Table 96. GlaxoSmithKline Product
Table 97. GlaxoSmithKline Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 98. GlaxoSmithKline Recent Development
Table 99. Mallinckrodt Pharmaceuticals Company Details
Table 100. Mallinckrodt Pharmaceuticals Business Overview
Table 101. Mallinckrodt Pharmaceuticals Product
Table 102. Mallinckrodt Pharmaceuticals Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 103. Mallinckrodt Pharmaceuticals Recent Development
Table 104. Hisamitsu Pharmaceutical Company Details
Table 105. Hisamitsu Pharmaceutical Business Overview
Table 106. Hisamitsu Pharmaceutical Product
Table 107. Hisamitsu Pharmaceutical Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 108. Hisamitsu Pharmaceutical Recent Development
Table 109. Impax Laboratories Business Overview
Table 110. Impax Laboratories Product
Table 111. Impax Laboratories Company Details
Table 112. Impax Laboratories Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 113. Impax Laboratories Recent Development
Table 114. Johnson ＆Johnson Company Details
Table 115. Johnson ＆Johnson Business Overview
Table 116. Johnson ＆Johnson Product
Table 117. Johnson ＆Johnson Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 118. Johnson ＆Johnson Recent Development
Table 119. UCB Company Details
Table 120. UCB Business Overview
Table 121. UCB Product
Table 122. UCB Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 123. UCB Recent Development
Table 124. Purdue Parma Company Details
Table 125. Purdue Parma Business Overview
Table 126. Purdue Parma Product
Table 127. Purdue Parma Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Business (2015-2020) (Million US$)
Table 128. Purdue Parma Recent Development
Table 129. Research Programs/Design for This Report
Table 130. Key Data Information from Secondary Sources
Table 131. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Type: 2020 VS 2026
Figure 2. Stimulants Features
Figure 3. Non-Stimulants Features
Figure 4. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Application: 2020 VS 2026
Figure 5. Specialty Clinics Case Studies
Figure 6. Hospital Pharmacies Case Studies
Figure 7. Retail Pharmacies Case Studies
Figure 8. E-Commerce Case Studies
Figure 9. Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Report Years Considered
Figure 10. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth 2015-2026 (US$ Million)
Figure 11. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions: 2020 VS 2026
Figure 12. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Regions (2021-2026)
Figure 13. Porter's Five Forces Analysis
Figure 14. Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Share by Players in 2019
Figure 15. Global Top Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics as of 2019
Figure 16. The Top 10 and 5 Players Market Share by Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue in 2019
Figure 17. North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 18. Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 19. China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 20. Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 21. Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 22. India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 23. Central & South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size YoY Growth (2015-2020) (Million US$)
Figure 24. Bottom-up and Top-down Approaches for This Report
Figure 25. Data Triangulation
Figure 26. Key Executives Interviewed

---